Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia

G. B. Martinelli, D. Olivari, A. D. Re Cecconi, L. Talamini, L. Ottoboni, S. H. Lecker, C. Stretch, V. E. Baracos, O. F. Bathe, A. Resovi, R. Giavazzi, L. Cervo, R. Piccirillo

Research output: Contribution to journalArticle

Abstract

Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.Oncogene advance online publication, 23 May 2016; doi:10.1038/onc.2016.153.

Original languageEnglish
Pages (from-to)6212-6222
JournalOncogene
Volume35
DOIs
Publication statusPublished - 2016

Fingerprint

Chemokine CXCL12
CXC Chemokines
Cachexia
Muscular Atrophy
Chemokine Receptors
Muscles
Skeletal Muscle Fibers
Neoplasms
Proteins
Muscle Neoplasms
p21-Activated Kinases
Rectus Abdominis
Critical Pathways
Kidney Neoplasms
Uremia
Ligases
Ubiquitin
Oncogenes
Adenylyl Cyclases
Protein Kinases

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Martinelli, G. B., Olivari, D., Re Cecconi, A. D., Talamini, L., Ottoboni, L., Lecker, S. H., ... Piccirillo, R. (2016). Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. Oncogene, 35, 6212-6222. https://doi.org/10.1038/onc.2016.153

Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. / Martinelli, G. B.; Olivari, D.; Re Cecconi, A. D.; Talamini, L.; Ottoboni, L.; Lecker, S. H.; Stretch, C.; Baracos, V. E.; Bathe, O. F.; Resovi, A.; Giavazzi, R.; Cervo, L.; Piccirillo, R.

In: Oncogene, Vol. 35, 2016, p. 6212-6222.

Research output: Contribution to journalArticle

Martinelli, GB, Olivari, D, Re Cecconi, AD, Talamini, L, Ottoboni, L, Lecker, SH, Stretch, C, Baracos, VE, Bathe, OF, Resovi, A, Giavazzi, R, Cervo, L & Piccirillo, R 2016, 'Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia', Oncogene, vol. 35, pp. 6212-6222. https://doi.org/10.1038/onc.2016.153
Martinelli GB, Olivari D, Re Cecconi AD, Talamini L, Ottoboni L, Lecker SH et al. Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. Oncogene. 2016;35:6212-6222. https://doi.org/10.1038/onc.2016.153
Martinelli, G. B. ; Olivari, D. ; Re Cecconi, A. D. ; Talamini, L. ; Ottoboni, L. ; Lecker, S. H. ; Stretch, C. ; Baracos, V. E. ; Bathe, O. F. ; Resovi, A. ; Giavazzi, R. ; Cervo, L. ; Piccirillo, R. / Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. In: Oncogene. 2016 ; Vol. 35. pp. 6212-6222.
@article{5c3c119e87fe4c8b87841b69cc167473,
title = "Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia",
abstract = "Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20{\%}, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.Oncogene advance online publication, 23 May 2016; doi:10.1038/onc.2016.153.",
author = "Martinelli, {G. B.} and D. Olivari and {Re Cecconi}, {A. D.} and L. Talamini and L. Ottoboni and Lecker, {S. H.} and C. Stretch and Baracos, {V. E.} and Bathe, {O. F.} and A. Resovi and R. Giavazzi and L. Cervo and R. Piccirillo",
year = "2016",
doi = "10.1038/onc.2016.153",
language = "English",
volume = "35",
pages = "6212--6222",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia

AU - Martinelli, G. B.

AU - Olivari, D.

AU - Re Cecconi, A. D.

AU - Talamini, L.

AU - Ottoboni, L.

AU - Lecker, S. H.

AU - Stretch, C.

AU - Baracos, V. E.

AU - Bathe, O. F.

AU - Resovi, A.

AU - Giavazzi, R.

AU - Cervo, L.

AU - Piccirillo, R.

PY - 2016

Y1 - 2016

N2 - Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.Oncogene advance online publication, 23 May 2016; doi:10.1038/onc.2016.153.

AB - Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (α, β, γ) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1α or SDF1β had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time- and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.Oncogene advance online publication, 23 May 2016; doi:10.1038/onc.2016.153.

UR - http://www.scopus.com/inward/record.url?scp=84969785084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969785084&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.153

DO - 10.1038/onc.2016.153

M3 - Article

AN - SCOPUS:84969785084

VL - 35

SP - 6212

EP - 6222

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -